Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.
Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.
In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.
Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.
With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.
Pfizer (PFE) has received FDA accelerated approval for BRAFTOVI® combination with cetuximab and mFOLFOX6 as the first-line treatment for metastatic colorectal cancer with BRAF V600E mutation. The approval is based on the Phase 3 BREAKWATER trial results, which showed a 61% overall response rate compared to 40% in the control arm. The median duration of response was 13.9 months versus 11.1 months for the control group.
This marks the first and only combination regimen with targeted therapy approved for first-line use in this patient population. The safety profile was consistent with known profiles of each agent, with common adverse reactions including peripheral neuropathy, nausea, and fatigue. The approval was granted under FDA's Project FrontRunner initiative.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for 10:30 a.m. EST on Tuesday, February 4, 2025. The call will discuss Pfizer's Fourth Quarter and Full Year 2024 Performance Report, which will be released that morning.
Investors and the public can access the webcast through www.pfizer.com/investors. Participants can join via webcast or by phone using the following numbers: 800-456-4352 (US/Canada) or 785-424-1086 (International), with passcode '30674'. The webcast replay and transcript will be available within 24 hours after the call and accessible for at least 90 days on Pfizer's investor website.
Grindr announced that its Roam feature, which allows users to explore and connect with locals worldwide, will be available for free during a 12-day holiday period from December 22 to January 2 in the U.S., sponsored by ViiV Healthcare. Typically priced at $5.99 per hour, Roam enables users to have their profiles appear on local grids in different cities or countries, facilitating connections for travel planning, relocation, or virtual exploration. The feature, launched earlier this year, has already helped thousands of users connect with locals before visiting new destinations.
Pfizer (PFE) has provided its full-year 2025 guidance, projecting revenue between $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company expects operational revenue growth of flat to 5% compared to 2024, with adjusted diluted EPS operational growth of 10% to 18%.
The company has achieved its goal of $4.0 billion in net cost savings through 2024 and anticipates an additional $500 million in savings in 2025. The guidance considers a $1 billion unfavorable impact from the Inflation Reduction Act Part D Redesign changes. Pfizer's 2025 adjusted expenses are projected at $13.3 to $14.3 billion for SI&A and $10.7 to $11.7 billion for R&D.
Pfizer (NYSE: PFE) has announced an increase in its quarterly cash dividend to $0.43 per share for the first quarter of 2025. The dividend will be paid on March 7, 2025, to shareholders of record as of January 24, 2025. This marks Pfizer's 345th consecutive quarterly dividend payment, demonstrating the company's commitment to shareholder returns. Chairman and CEO Dr. Albert Bourla emphasized that this dividend increase reflects Pfizer's strong financial performance and disciplined execution.
Pfizer (PFE) and Alliance Foundation Trials announced significant results from the Phase 3 PATINA trial for IBRANCE® in treating HR+, HER2+ metastatic breast cancer. The trial demonstrated that adding IBRANCE to standard first-line maintenance therapy significantly improved progression-free survival (PFS). Patients treated with IBRANCE combination therapy achieved a median PFS of 44.3 months compared to 29.1 months for those on standard therapy alone, representing a 15-month improvement.
The safety profile aligned with previous known data, with common adverse events including neutropenia, leukopenia, fatigue, stomatitis, and diarrhea. IBRANCE, approved since 2015, has been prescribed to over 773,000 patients and is approved in more than 108 countries. Pfizer plans to present these findings to regulatory authorities.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for December 17, 2024, at 8:30 a.m. EST. The primary purpose is to present the company's full-year 2025 financial guidance.
Investors and the public can access the webcast through www.pfizer.com/investors. Participants can join via webcast or by phone using the following numbers: 800-456-4352 (US/Canada) or 785-424-1086 (international), with passcode '85344'.
The webcast replay and transcript will be available on Pfizer's investor website within 24 hours after the live call and will remain accessible for at least 90 days.
Scorpion Therapeutics announced updates for its PI3Kα inhibitor STX-478, including a new collaboration with Pfizer to evaluate a triplet combination therapy for metastatic breast cancer. The collaboration will study STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer, with trial initiation planned for 2H25.
Updated Phase 1/2 study results presented at SABCS 2024 showed STX-478 achieved a 23% overall response rate in HR+/HER2- breast cancer and 44% ORR in gynecological tumors. The drug demonstrated favorable safety with minimal dose modifications and no patient discontinuations due to adverse events. The study also revealed a positive dose-response relationship in monotherapy treatment.
Pfizer will present over 100 research abstracts at the American Society of Hematology (ASH) Annual Meeting and San Antonio Breast Cancer Symposium (SABCS) in December. The presentations include data from approved medicines and pipeline candidates for blood and breast cancers, and rare blood disorders.
Key highlights include updated analyses from the ECHELON-3 trial for ADCETRIS in DLBCL, new data for ELREXFIO in multiple myeloma, and nine real-world analyses confirming IBRANCE as a first-line treatment for HR+/HER2- metastatic breast cancer. The company will also present new Phase 1 data for innovative therapies including atirmociclib, vepdegestrant, and PF-07248144.
The presentations span multiple therapeutic areas including hemophilia, with results from the Phase 3 AFFINE gene therapy trial, and sickle cell disease research.
Zai Lab (NASDAQ: ZLAB) and Pfizer announced a strategic collaboration for XACDURO® (sulbactam-durlobactam) in mainland China through November 2028. Pfizer will exclusively handle commercialization activities for XACDURO®, leveraging its anti-infective infrastructure. XACDURO® is the only antimicrobial specifically developed for treating carbapenem-resistant Acinetobacter baumannii (CRAB) in hospital-acquired and ventilator-associated bacterial pneumonia. In China, where Acinetobacter baumannii resistance to carbapenem antibiotics has reached approximately 74%, this collaboration aims to accelerate patient access to this critical therapy.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
What is Pfizer Inc. known for?
Where is Pfizer's headquarters located?
How much does Pfizer make annually?
What are some of Pfizer's top-selling products?
What is the significance of Pfizer's international sales?
What recent collaborations has Pfizer been involved in?
When was Pfizer founded?
What is Pfizer's approach to innovation?
How does Pfizer contribute to cancer treatment?
What role do strategic partnerships play for Pfizer?
